Back to search results

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Ovarian Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The University of Chicago Medical Center, Chicago, Illinois, United States

    Contact: Study coordinator (John Moroney) · 773-834-4732

  • BCCA - Kelowna, Kelowna, British Columbia, Canada

    Contact: Study coordinator (Susan Ellard) · 250 712-3900

  • BCCA - Vancouver, Vancouver, British Columbia, Canada

    Contact: Study coordinator (Anna Tinker) · 604 877-6000

  • Odette Cancer Centre, Toronto, Ontario, Canada

    Contact: Study coordinator (Helen MacKay) · 416 480-5145

  • University Health Network, Toronto, Ontario, Canada

    Contact: Study coordinator (Stephanie Lheureux) · 416 946-4501

  • CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada

    Contact: Study coordinator (Diane Provencher) · 514 890-8444
Study leads

  • Helen MacKay

    Study Chair

    Sunnybrook Health Sciences Centre, Toronto, Ontario Canada

  • Anna Tinker

    Study Chair

    BCCA - Vancouver Cancer Centre, BC Canada

View source on ClinicalTrials.gov(opens in a new tab)